Grohmann, Gary

Dr Gary Grohmann

Virologist; Consultant, World Health Organisation; Board Member, Immunisation Coalition; Former Director, Immunobiology at the TGA; Adjunct Professor, Faculty of Medicine, University of Sydney
Dr. Gary Grohmann B. Sc. (Hons), PhD, FASM Gary Grohmann is former Director of Immunobiology and WHO ERL at the TGA, Office of Laboratories and Scientific services from 1997-2015. He currently works as an independent consultant, primarily with the WHO on influenza related projects in the Global Influenza Programme and the Essential Medicines Programme.

Dr. Grohmann has served on several WHO steering committees including the committee for the review of the IVTM database on influenza viruses and reassortant influenza viruses, and the WHO VCM committee that recommends virus strains for influenza vaccines (until 2015). He has also been a member of the Technical Advisory Group (2007-2015) of the Global Action Plan for Influenza.

His primary interests are in vaccines, vaccine regulation, medical and veterinary virology, and infectious diseases resulting from contaminated food and water as well as other environmental sources. Dr. Grohmann is currently a Board Member of the Immunisation Coalition and Adjunct Professor at the University of Sydney.

More from this expert

Podcasts iconPodcasts

Antiviral drugs and other therapeutics, new drugs and vaccines in the pipeline. Are universal vaccines a pipe dream? Why vaccines are only part of the answer and will never control the pandemic?

Transitioning our patients to Novavax and protein-based vaccines and away from mRNA. Monkeypox should be taken seriously... especially for high-risk patients

Podcasts iconPodcasts

Antiviral drugs and other therapeutics, new drugs and vaccines in the pipeline. Are universal vaccines a pipe dream? Why vaccines are only part of the answer and will never control the pandemic?

Podcasts iconPodcasts

The pros and cons of a 5th jab for health workers, whether we have reached the end of the road with mRNA-based vaccines, cutting through the subvariant hype, new vaccines on the horizon, and the 2023 forecast - does ATAGI need a rethink?

Podcasts iconPodcasts

How healthy young people will derive little benefit from a fourth or fifth dose of vaccine, and how we should keep them for the vulnerable population, and China's response to the COVID surge being of global interest and concern

Podcasts iconPodcasts

A massive surge in Omicron infections in China likely means new subvariants—and potentially worse.

Clinical Articles iconClinical Articles

Zinc, Selenium, Melatonin, and Vitamin D supplements are useful adjuncts in the early stages of COVID-19 infection

Podcasts iconPodcasts

Dr Gary Grohmann and Prof Robert Booy weigh up the research on boosters

Clinical Articles iconClinical Articles

Are the bivalent vaccines what they are cracked up to be? Plus the origin of COVID-19

Podcasts iconPodcasts

How do we tell the public it is not over? Are mask beneficial? How to justify the use of vaccines that can cause serious adverse reactions in healthy people.

Podcasts iconPodcasts

The WHO says the emergency is over - should we believe them? 2nd generation vaccines are needed- vaccine related injury.

Podcasts iconPodcasts

Vaccine-related injury, long COVID, more on boosters.

Podcasts iconPodcasts

What’s happening in China now? Multiresistant mycoplasma infection may be the issue, ad the latest on new COVID vaccines arriving next week and in the next few months

Podcasts iconPodcasts